Lionel Carnot

About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness[1] – and we are aiming to seek market approval in the US. We believe MINIject’s unique tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of best-in-class products such as MINIject to establish new treatment paradigms in eye care conditions with the highest patient needs. About MINIject® MINIject is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About Glaucoma Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[1][2] IOP reduction, through medication or surgery, helps delay disease progression.[3] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.[2] MINIject is potentially best-in-class for its promising long-term efficacy and safety. [1] Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93 [2] Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report [3] “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73 MINIject is a registered trademark in the European Union.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

Recommended by 98% of physicians and 90% of users, INNOVO is the perfect solution for treating stress urinary incontinence. Safe, effective and FDA-cleared, INNOVO offers the only clinically-proven, wearable and truly non-invasive solution for stress urinary incontinence (SUI). Using unique multipath™ technology, INNOVO targets the weakened pelvic floor muscles, delivering 180 perfect and complete pelvic floor contractions over each 30-minute session.

About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness[1] – and we are aiming to seek market approval in the US. We believe MINIject’s unique tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of best-in-class products such as MINIject to establish new treatment paradigms in eye care conditions with the highest patient needs. About MINIject® MINIject is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About Glaucoma Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[1][2] IOP reduction, through medication or surgery, helps delay disease progression.[3] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.[2] MINIject is potentially best-in-class for its promising long-term efficacy and safety. [1] Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93 [2] Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report [3] “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73 MINIject is a registered trademark in the European Union.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

Recommended by 98% of physicians and 90% of users, INNOVO is the perfect solution for treating stress urinary incontinence. Safe, effective and FDA-cleared, INNOVO offers the only clinically-proven, wearable and truly non-invasive solution for stress urinary incontinence (SUI). Using unique multipath™ technology, INNOVO targets the weakened pelvic floor muscles, delivering 180 perfect and complete pelvic floor contractions over each 30-minute session.

Founded in 1997, Pan-European VC Earlybird backs exceptional early-stage companies, supporting them through their growth and development phases and providing financial resources, strategic support, plus access to an international network and capital markets. Through two separate strategies, Earlybird focuses on tech-enabled businesses across software applications, infrastructure, and deep tech, while Earlybird Health focuses on life science breakthroughs accelerated by data-driven analytics and operations. Earlybird also has a pro-bono impact initiative, Vision Lab. With EUR 2.5 billion under management across fund streams and a history of 9 IPOs and 37 trade sales, Earlybird is among Europe’s most established and active venture capital firms. More information: www.earlybird.com X: https://x.com/EarlybirdVC LinkedIn:www.linkedin.com/company/earlybird-venture-capital Instagram: https://www.instagram.com/earlybirdvc/

Founded in 1997, Bay City Capital LLC is a life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. Our investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of our partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members.